表紙
市場調査レポート

EpiCast Report:加齢黄斑変性症の疫学予測

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 312373
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
EpiCast Report:加齢黄斑変性症の疫学予測 EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023
出版日: 2014年09月10日 ページ情報: 英文 38 Pages
概要

加齢黄斑変性症(AMD)は、網膜で中心視野を担う、黄斑の段階的な劣化によって引き起こされる、進行性の眼疾患です。世界の主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)における加齢黄斑変性症(AMD)の有病件数は、2013年の55,770,401件から、今後10年間で66,069,370件まで、18.5%増加すると予測されています。

当レポートでは、世界の主要7ヶ国における加齢黄斑変性症(AMD)について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • 主要5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
  • AMDの疫学予測
    • AMDの総有病件数
    • AMDの総有病件数:年齢別
    • AMDの総有病件数:性別
    • AMDの総有病率:年齢標準化
    • AMDの総有病件数:段階別
    • AMD後期の総有病件数:サブタイプ別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER066-14

Age-related macular degeneration (AMD) is a progressive eye condition caused by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly in developed countries. In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual. AMD is classified into two stages: early AMD and late AMD. Late AMD is the advanced stage of AMD, which is further subclassified into dry AMD (geographic atrophy) and wet AMD (neovascular).

GlobalData epidemiologists forecast that the total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of AMD, followed by Japan.

GlobalData's epidemiological analysis is supported by the use of total prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of AMD; GlobalData epidemiologists segmented AMD by stages (early AMD and late AMD, and the late AMD subtypes: dry AMD and wet AMD), which allows for a meaningful comparison of the disease populations between markets.

Scope

  • The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AMD segmented by sex and age (50-59 years, 60-69 years, 70-79 years, and =80 years) in these markets. Additionally, GlobalData epidemiologists provide the total prevalent cases of AMD segmented by AMD stages: early AMD and late AMD, as well as the late AMD subtypes: dry AMD and wet AMD.
  • The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AMD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for AMD (2013-2023)
    • 3.5.1. Total Prevalent Cases of AMD
    • 3.5.2. Age-Specific Total Prevalent Cases of AMD
    • 3.5.3. Sex-Specific Total Prevalent Cases of AMD
    • 3.5.4. Age-Standardized Total Prevalence of AMD
    • 3.5.5. Total Prevalent Cases of AMD by Stage
    • 3.5.6. Total Prevalent Cases of Late AMD by Subtype
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for AMD
  • Table 2: Diagnostic Criteria for AMD
  • Table 3: 7MM, Sources of AMD Prevalence Data
  • Table 4: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
  • Table 5: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013
  • Table 6: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N (Row %), 2013
  • Table 7: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N (Row %), 2013
  • Table 8: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N (Row %), 2013

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013
  • Figure 3: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age ≥50 Years, by Sex, 2013
  • Figure 5: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N, 2013
  • Figure 6: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N, 2013
Back to Top